Companies ›Healthcare ›DTIL

DTIL — Nasdaq Pharmaceuticals

Precision Biosciences Inc

$7,06

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

173,9M USD

P/E

—

EV / Rev

1,9x

Div yield

—

Op margin

-152,2 %

ROE

-60,1 %

Net margin

-133,4 %

Debt / equity

—

Beta

—

52w range

—

Volume

2,5k

Day range

$6,72–$7,10

Prev close

$6,95

Open

$6,91

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Precision BioSciences operates as a clinical-stage biotechnology company developing gene-editing therapies, generating revenue primarily through collaboration and license agreements with partners such as Novartis Pharma AG and iECURE.

Business. Precision Biosciences Inc (DTIL) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification93 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY5 analysts

5 buy0 hold0 sell

Avg 12m price target29,60

Analyst recommendations

5 analysts · consensus Buy

Buy5

Hold0

Sell0

12-month price target

29,60

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

5 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

-60,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning DTIL.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to DTIL. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Precision Biosciences Inc (DTIL) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification93 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

Precision BioSciences maintains a robust liquidity position with $99.4 million in cash and equivalents against total liabilities of $67.8 million, resulting in a current ratio of 14.02 and a debt-to-equity ratio of 0.0. The company carries no long-term debt, relying entirely on equity financing to fund operations. The market capitalization stands at $166.0 million, trading at a price-to-book ratio of 2.21. While the balance sheet is strong, the company generates negative operating cash flow of $11.9 million in Q1 2026, indicating ongoing reliance on capital markets or existing cash reserves to sustain operations.

Profitability remains negative as the company is in the development phase. Net income for Q1 2026 was -$18.4 million, with an operating loss of -$9.1 million. Return on equity is -60.1% and return on assets is -31.8%, reflecting the significant investment required for research and development relative to the current asset base. Revenue for the quarter was $10.8 million, primarily derived from milestone payments and license fees rather than product sales. The EV/EBITDA ratio is negative, consistent with pre-commercial biotech firms.

Revenue concentration is high, driven by specific partnership agreements. Key partners identified in filings include Novartis Pharma AG, iECURE, and Imugene. The company’s operating segments are defined by its therapeutic programs, including the PBGENE Hepatitis B Virus program, the PBGENE Duchenne Muscular Dystrophy program, and the PBGENE 3243 program. Geographic exposure is predominantly domestic, with research and development activities centered in the United States.

Growth trajectory is characterized by intermittent revenue spikes from license milestones rather than linear organic growth. The company has executed public offerings in March 2024 and November 2025 to raise capital, with the March 2024 offering generating approximately $37.0 million in net proceeds. Revenue recognition is tied to the achievement of clinical and regulatory milestones under its collaboration agreements, leading to volatility in quarterly top-line figures.

Risk factors include medium dilution risk due to the company’s history of equity issuances and outstanding warrants from the March 2024 and November 2025 public offerings. Liquidity risk is assessed as low given the substantial cash position, but the company faces execution risk in advancing its clinical programs. Key flags in source documents mention dilution or offering risk, highlighting the potential for further share issuance to fund future development stages.

Recent events include the filing of a Q1 2026 10-Q and an 8-K with material item 5.02, indicating a significant corporate event or agreement. Analyst sentiment remains positive, with a mean recommendation of 1.40 (strong buy) and a mean price target of $29.60, significantly above the current market price of $6.74. The company continues to advance its gene-editing platform, leveraging partnerships to de-risk development costs.

Key takeaways

Strong liquidity position with $99.4 million in cash and no debt, providing a multi-year runway for development.
Negative profitability with -$18.4 million net income in Q1 2026, typical for clinical-stage biotechs.
High revenue concentration from partnership milestones with Novartis, iECURE, and Imugene.
Medium dilution risk due to outstanding warrants and history of equity offerings.
Positive analyst sentiment with a mean price target of $29.60 vs. current price of $6.74.
Recent 8-K filing with material item 5.02 suggests significant corporate developments.

Bull / Bear case

Generated · model-assisted

BULL CASE · 5

Analysts project 339% upside to a mean price target of $29.60, reflecting strong buy consensus.

The company maintains a debt-to-equity ratio of 0.67, placing it in the top quartile for leverage safety.

Revenue grew 100.5% year-over-year to $68.7 million in FY2025, demonstrating significant top-line expansion.

Cash conversion metrics rank above the pharmaceutical cohort median, indicating superior operational efficiency relative to peers.

Liquidity risk is assessed as low, supported by a robust current ratio of 13.32.

BEAR CASE · 2

The company faces medium dilution risk, which could negatively impact existing shareholder value over time.

Institutional ownership is extremely low with only 10 holders, suggesting limited institutional confidence or interest.

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Revenue $10.8M; Operating income -$9.1M.

Revenue$10.8M

Operating income-$9.1M

Net income-$18.4M

Free cash flow—

EPS—

Operating cash flow-$11.9M

Financials

Income statement

Revenue$10.8M

Gross profit—

Operating income-$9.1M

Net income-$18.4M

Margins

Gross margin—

Operating margin-83.7%

Net margin-170.2%

FCF margin—

Balance sheet

Total assets$143.9M

Total liabilities$67.8M

Total equity$76.1M

Cash & equivalents$99.4M

Long-term debt—

Cash flow

Operating cash flow-$11.9M

CapEx—

Free cash flow—

SBC$1.5M

P&L flow · revenue → net income

Highlights

▍Revenue $10.8M
▍Operating income -$9.1M
▍Net margin -170.2%

Valuation FY

Market price

$7,06

Market cap

$166.0M

Enterprise valueⓘ

$64.9M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

1.9x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

2.2x

P / Tangible bookⓘ

2.2x

Tangible book

$75.0M

Net cashⓘ

$101.2M

Current ratioⓘ

14.0

Debt / equityⓘ

—

ROAⓘ

-31.8%

ROEⓘ

-60.1%

Cash conversionⓘ

144.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

29.7%

Dilution ratioⓘ

-4.5%

Revenue by segment

Business relationships

Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures

Partners3

Caribou Biosciences IncCRBU.OPartner95%Source ↗

Tg Therapeutics IncTGTX.OPartner95%Source ↗

Imugene LtdIMU.AXPartner90%Source ↗

Supply chain

Vendors → DTIL ↔ Partners → Customers · click any node to drill

3 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-2,81

Predicted surprise

-0,08

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-07-28 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-2,81
Revenue	—no estimate	—no estimate	18,6M USD
Operating income	—no estimate	—no estimate	-75,0M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution5 analysts

Strong buy3

Buy2

Hold0

Sell0

Strong sell0

12-month price target$29,60 · Median $20,00

Low $19,00High $60,00

Operating income · consensus-75,0M USD

EPS surprise

−26,9 %

reported vs consensus · miss

Revenue surprise

+83,7 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$19,00

Mean$29,60

Median$20,00

High$60,00

Spot$7,06

+319.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskMedium

Liquidity riskLow

Filing-based flags

Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-152,2 %Bottom quartile

Net Margin-133,4 %Bottom quartile

ROE-60,1 %Bottom quartile

D/E0,00Above P75

Cash Conv1,44Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 589 531 sh21 exercises · 9 grants9 insiders

Pire Shari LisaDirector · Restricted Stock Units → Common StockAcquired 20 979grant · 2026-06-03
Buehler KevinDirector · Restricted Stock Units → Common StockAcquired 20 979grant · 2026-06-03
Brown MelindaDirector · Restricted Stock Units → Common StockAcquired 20 979grant · 2026-06-03
Frankel StanleyDirector · Restricted Stock Units → Common StockAcquired 20 979grant · 2026-06-03
Germano Geno JDirector · Restricted Stock Units → Common StockAcquired 20 979grant · 2026-06-03
SMITH J. JEFFERSONChief Research Officer · Restricted Stock Units → Common StockAcquired 57 389grant · 2026-06-01
Amoroso MichaelDirector, President and CEO · Restricted Stock Units → Common StockAcquired 573 888grant · 2026-06-01
Kelly John AlexanderChief Financial Officer · Restricted Stock Units → Common StockAcquired 193 688grant · 2026-06-01
Scimeca DarioGeneral Counsel and Secretary · Restricted Stock Units → Common StockAcquired 107 604grant · 2026-06-01
Pire Shari LisaDirector · Restricted Stock Units → Common StockDisposed 21 000exercise · 2026-05-20
Buehler KevinDirector · Restricted Stock Units → Common StockDisposed 21 000exercise · 2026-05-20
Germano Geno JDirector · Restricted Stock Units → Common StockDisposed 21 000exercise · 2026-05-20
Frankel StanleyDirector · Restricted Stock Units → Common StockDisposed 21 000exercise · 2026-05-20
Brown MelindaDirector · Restricted Stock Units → Common StockDisposed 21 000exercise · 2026-05-20
Scimeca DarioGeneral Counsel and Secretary · Restricted Stock Units → Common StockDisposed 16 667exercise · 2026-02-17
Kelly John AlexanderChief Financial Officer · Restricted Stock Units → Common StockDisposed 27 584exercise · 2026-02-17
Amoroso MichaelDirector, President and CEO · Restricted Stock Units → Common StockDisposed 67 797exercise · 2026-02-17
SMITH J. JEFFERSONChief Research Officer · Restricted Stock Units → Common StockDisposed 16 667exercise · 2026-02-17
Scimeca DarioGeneral Counsel and Secretary · Restricted Stock Units → Common StockDisposed 8 425exercise · 2026-01-20
Scimeca DarioGeneral Counsel and Secretary · Restricted Stock Units → Common StockDisposed 14 908exercise · 2026-01-20
Kelly John AlexanderChief Financial Officer · Restricted Stock Units → Common StockDisposed 3 888exercise · 2026-01-20
Kelly John AlexanderChief Financial Officer · Restricted Stock Units → Common StockDisposed 13 900exercise · 2026-01-20
SMITH J. JEFFERSONChief Research Officer · Restricted Stock Units → Common StockDisposed 16 219exercise · 2026-01-20
Amoroso MichaelDirector, President and CEO · Restricted Stock Units → Common StockDisposed 8 888exercise · 2026-01-20
Amoroso MichaelDirector, President and CEO · Restricted Stock Units → Common StockDisposed 37 069exercise · 2026-01-20

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Price To Tangible Book
market_price / (tangible_book_value / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Return On Equity
net_income / total_equity
Enterprise Value
market_cap - net_cash
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

PRECISION BIOSCIENCES INC company facts · 2026-07-28
PRECISION BIOSCIENCES INC 10-Q 2026-05-05 · 2026-07-28
PRECISION BIOSCIENCES INC 10-K 2026-03-12 · 2026-07-28
PRECISION BIOSCIENCES INC 10-Q 2025-11-03 · 2026-07-28
PRECISION BIOSCIENCES INC 10-Q 2025-08-07 · 2026-07-28
8-K (sec_8k_material) on DTIL · 2026-07-28
Precision BioSciences Inc Market data — analyst estimates · 2026-07-28
Precision BioSciences Inc Market data — ESG · 2026-07-28
PRECISION BIOSCIENCES INC HA canonical relationships · 2026-07-28

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$4M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$1M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Net selling3 buys · 8 sellsnet -$398K9 insiders · last 365d

Brown MelindaDirector · Common StockOther 21 000 · 2026-05-20
Germano Geno JDirector · Common StockOther 21 000 · 2026-05-20
Buehler KevinDirector · Common StockOther 21 000 · 2026-05-20
Frankel StanleyDirector · Common StockOther 21 000 · 2026-05-20
Pire Shari LisaDirector · Common StockOther 21 000 · 2026-05-20
Amoroso MichaelDirector, President and CEO · Common StockSold 20 559 @ $3,84$79K · 2026-02-18
SMITH J. JEFFERSONChief Research Officer · Common StockSold 4 925 @ $3,84$19K · 2026-02-18
Kelly John AlexanderChief Financial Officer · Common StockSold 8 149 @ $3,84$31K · 2026-02-18
Scimeca DarioGeneral Counsel and Secretary · Common StockSold 4 925 @ $3,84$19K · 2026-02-18
SMITH J. JEFFERSONChief Research Officer · Common StockOther 16 667 · 2026-02-17
Amoroso MichaelDirector, President and CEO · Common StockOther 67 797 · 2026-02-17
Kelly John AlexanderChief Financial Officer · Common StockOther 27 584 · 2026-02-17
Scimeca DarioGeneral Counsel and Secretary · Common StockOther 16 667 · 2026-02-17
Amoroso MichaelDirector, President and CEO · Common StockSold 34 799 @ $4,17$145K · 2026-01-22
SMITH J. JEFFERSONChief Research Officer · Common StockSold 10 200 @ $4,03$41K · 2026-01-21
Scimeca DarioGeneral Counsel and Secretary · Common StockSold 8 854 @ $4,03$36K · 2026-01-21
Kelly John AlexanderChief Financial Officer · Common StockSold 15 213 @ $4,03$61K · 2026-01-21
SMITH J. JEFFERSONChief Research Officer · Common StockOther 16 219 · 2026-01-21
Scimeca DarioGeneral Counsel and Secretary · Common StockOther 8 425 · 2026-01-20
Scimeca DarioGeneral Counsel and Secretary · Common StockOther 14 908 · 2026-01-20
Kelly John AlexanderChief Financial Officer · Common StockOther 3 888 · 2026-01-20
Kelly John AlexanderChief Financial Officer · Common StockOther 13 900 · 2026-01-20
Kelly John AlexanderChief Financial Officer · Common StockOther 26 575 · 2026-01-20
SMITH J. JEFFERSONChief Research Officer · Common StockOther 2 500 · 2026-01-20
SMITH J. JEFFERSONChief Research Officer · Common StockOther 10 447 · 2026-01-20

Short positioning

2.4Mshares short+3.8% vs prior

3.6days to cover

34.5%short of daily vol

51.8Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

DTILCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob45 %Surprise-0,08Full forecast →

peak dispatch · —

OSINT findings

Dilution riskMedium

Liquidity riskLow

Source documents mention dilution or offering risk.

Relationship graph

This companySectorPartners

Evidence & claims

From filings & derived data

EPS (basic) (annual): USD-PER-SHARES -4Unknown
Current liabilities (annual): USD 8.91MUnknown
Total liabilities (annual): USD 62.17MUnknown
Net income (annual): USD -45.72MUnknown
Current assets (annual): USD 118.74MUnknown
R&D expense (annual): USD 54.17MUnknown
EPS (diluted) (annual): USD-PER-SHARES -4Unknown
Total assets (annual): USD 154.42MUnknown
Operating cash flow (annual): USD -65.84MUnknown
Shareholders' equity (annual): USD 92.25MUnknown
Cash & equivalents (annual): USD 110.82MUnknown
Total operating expenses (annual): USD 86.41MUnknown
Shares outstanding (annual): 24.09MUnknown
Operating income (annual): USD -52.15MUnknown
Revenue (annual): USD 34.26MUnknown
Total assets (YoY) (2025-12-31 vs 2024-12-31): 13.2%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -99.3%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -9.0%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -50.1%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 63.6%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -22.3%Derived (calculated)
Net margin (FY 2025-12-31): -133.4%Derived (calculated)
Return on equity (FY 2025-12-31): -49.6%Derived (calculated)
Return on assets (FY 2025-12-31): -29.6%Derived (calculated)

Showing 24 of 52 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-28 04:34 UTCFILINGMaterial 8-K

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-16FILING8-K filing →

2026-06-03 00:00 UTCINSIDER9 insider transactions — 2026-06 9 derivative

2026-06-03INSIDERBuehler Kevin acquired 21.0k sh Restricted Stock Units — Director

2026-06-03INSIDERPire Shari Lisa acquired 21.0k sh Restricted Stock Units — Director

2026-06-03INSIDERGermano Geno J acquired 21.0k sh Restricted Stock Units — Director

2026-06-03INSIDERFrankel Stanley acquired 21.0k sh Restricted Stock Units — Director

2026-06-03INSIDERBrown Melinda acquired 21.0k sh Restricted Stock Units — Director

2026-06-01INSIDERSMITH J. JEFFERSON acquired 57.4k sh Restricted Stock Units — Chief Research Officer

2026-06-01INSIDERScimeca Dario acquired 107.6k sh Restricted Stock Units — General Counsel and Secretary

2026-06-01INSIDERKelly John Alexander acquired 193.7k sh Restricted Stock Units — Chief Financial Officer

2026-06-01INSIDERAmoroso Michael acquired 573.9k sh Restricted Stock Units — Director, President and CEO

2026-05-27FILING8-K filing →

2026-05-26FILING8-K filing →

2026-05-20 00:00 UTCINSIDER10 insider transactions — 2026-05 5 derivative

2026-05-20INSIDERBrown Melinda transacted 21.0k sh — Director

2026-05-20INSIDERGermano Geno J transacted 21.0k sh — Director

2026-05-20INSIDERBuehler Kevin transacted 21.0k sh — Director

2026-05-20INSIDERFrankel Stanley transacted 21.0k sh — Director

2026-05-20INSIDERPire Shari Lisa transacted 21.0k sh — Director

2026-05-20INSIDERBuehler Kevin disposed of 21.0k sh Restricted Stock Units — Director

2026-05-20INSIDERFrankel Stanley disposed of 21.0k sh Restricted Stock Units — Director

2026-05-20INSIDERBrown Melinda disposed of 21.0k sh Restricted Stock Units — Director

2026-05-20INSIDERPire Shari Lisa disposed of 21.0k sh Restricted Stock Units — Director

2026-05-20INSIDERGermano Geno J disposed of 21.0k sh Restricted Stock Units — Director

2026-05-05FILING10-Q filing →

2026-05-05FILING8-K filing →

2026-04-08FILINGDEF 14A filing →

2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 10.8M · Net USD -18.4M

2026-03-17FILING8-K filing →

2026-03-12FILING10-K filing →

2026-03-12FILING8-K filing →

2026-02-18 00:00 UTCINSIDER12 insider transactions — 2026-02 · net sell $148k 4 derivative

2026-02-18INSIDERAmoroso Michael sold 20.6k sh — Director, President and CEO ~$79k

2026-02-18INSIDERSMITH J. JEFFERSON sold 4.9k sh — Chief Research Officer ~$19k

2026-02-18INSIDERKelly John Alexander sold 8.1k sh — Chief Financial Officer ~$31k

2026-02-18INSIDERScimeca Dario sold 4.9k sh — General Counsel and Secretary ~$19k

2026-02-17INSIDERSMITH J. JEFFERSON transacted 16.7k sh — Chief Research Officer

Showing the 40 most recent of 67 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread